North America Pharmaceutical CDMO Market Size is USD 80.12 Billion by 2026

North America Pharmaceutical CDMO Market (By Service Type: Active Pharmaceutical Ingredient (API) Manufacturing; Finished Dosage Formulation (FDF) Development and Manufacturing; Secondary Packaging; By Research Phase;:Pre-clinical; Phase I; Phase II; Phase III; Phase IV) Industry Size, Share, Growth, Trends 2025 to 2035

Report Code : 1332 | Published : 29 May 2026 | Delivery : Immediate | Format : Excel | Author : Aditi Shivarkar, Aman Singh

Revenue,

USD 75.02 Bn

Forecast Year,

USD 144.84 Bn

CAGR, 2026 - 2035

6.80%

Report Coverage

North America

Download Databook

The North America pharmaceutical CDMO market size was estimated at USD 75.02 billion in 2025 and is predicted to reach around USD 144.84 billion by 2035, expanding at a CAGR of 6.80% from 2026 to 2035. Growing trends of outsourcing and rising R&D investments are driving the market.

North America Pharmaceutical CDMO Market Statical Scope

Reports Attributes	Statistics
Market Size in 2025	USD 75.02 Billion
Market Size in 2026	USD 80.12 Billion
Market Size by 2035	USD 144.84 Billion
CAGR 2026 to 2035	6.80%
Base Year	2025
Forecast Period	2026 to 2035

North America boasts a strong presence of pharmaceutical and biotechnology companies dedicated to developing innovative products. The market is fueled by the growing demand for personalized medicines , increasing competition, and favorable regulatory support.

Government organizations provide funding for research and manufacturing activities, contributing to robust market growth. Additionally, there is a rise in collaborations among key players and an increasing adoption of advanced technologies.

Segments	Shares (%)
Finished Dosage Formulation (FDF) Development and Manufacturing	45%
Active Pharmaceutical Ingredient (API) Manufacturing	40%
Secondary Packaging	15%

Finished dosage formulation (FDF) development and manufacturing - Finished dosage formulation (FDF) development and manufacturing lead the market, holding a share of 45%, driven by increasing outsourcing of drug formulation processes and rising need for scalable manufacturing solutions among pharmaceutical companies.
Active pharmaceutical ingredient (API) manufacturing - Active pharmaceutical ingredient (API) manufacturing accounts for a significant share of 40%, supported by increasing demand for high -quality APIs and expanding outsourcing trends across drug development pipelines.
Secondary packaging - Secondary packaging holds 15% share, driven by growing requirements for product safety, regulatory compliance, labeling, and efficient supply chain management.

Segments	Shares (%)
Phase III	30%
Phase II	24%
Phase I	18%
Pre-clinical	15%
Phase IV	13%

Phase III - Phase III leads the market, holding a 30% share, driven by increasing late -stage drug development activities, higher investment in pivotal trials, and growing demand for large -scale manufacturing support.
Phase II - Phase II accounts for a significant share of 24%, supported by rising focus on efficacy studies and the expansion of mid -stage clinical pipelines.
Phase I - Phase I holds 18%, driven by growing early -stage clinical trials and increasing demand for small -scale manufacturing and testing services.
Pre -clinical - The pre -clinical phase represents 15% of the market, supported by increasing research and development activities and early drug discovery efforts.

Top Companies in the North America Pharmaceutical CDMO Market

Bushu Pharmaceuticals Ltd.
Nipro Corporation
Thermo Fisher Scientific Inc.
Samsung Biologics
Laboratory Corporation of America Holdings
Siegfried Holding Ag
Catalent, Inc
Lonza Group AG
Recipharm Ab
Piramal Pharma Solutions
Cordenpharma International
Cambrex Corporation
Wuxi Apptec

Segments Covered in the Report

By Service Type

Active Pharmaceutical Ingredient (API) Manufacturing
- Small Molecule
- Large Molecule
- High Potency (HPAPI)
Finished Dosage Formulation (FDF) Development and Manufacturing
- Solid Dose Formulation
- Tablets
- Others (Capsules, Powders, etc.)
- Liquid Dose Formulation
- Injectable Dose Formulation
Secondary Packaging

By Research Phase

Pre-clinical
Phase I
Phase II
Phase III
Phase IV

List of Tables & Figures

List of Tables

Table 1: North America Pharmaceutical CDMO Market Size, 2025-2035 (USD Billion)
Table 2: North America Pharmaceutical CDMO Market Size, by Service Type, 2025-2035 (USD Billion)
Table 3: North America Pharmaceutical CDMO Market Size, by Research Phase, 2025-2035 (USD Billion)
Table 4: North America Pharmaceutical CDMO Market Size, by Active Pharmaceutical Ingredient (API) Manufacturing, 2025-2035 (USD Billion)
Table 5: North America Pharmaceutical CDMO Market Size, by Finished Dosage Formulation (FDF) Development and Manufacturing, 2025-2035 (USD Billion)
Table 6: North America Pharmaceutical CDMO Market Size, by Secondary Packaging, 2025-2035 (USD Billion)
Table 7: North America Pharmaceutical CDMO Market Size, by Pre-clinical Phase, 2025-2035 (USD Billion)
Table 8: North America Pharmaceutical CDMO Market Size, by Phase I, 2025-2035 (USD Billion)
Table 9: North America Pharmaceutical CDMO Market Size, by Phase II, 2025-2035 (USD Billion)
Table 10: North America Pharmaceutical CDMO Market Size, by Phase III, 2025-2035 (USD Billion)
Table 11: North America Pharmaceutical CDMO Market Size, by Phase IV, 2025-2035 (USD Billion)
Table 12: U.S. Pharmaceutical CDMO Market Size, 2025-2035 (USD Billion)
Table 13: U.S. Market Size, by Service Type, 2025-2035 (USD Billion)
Table 14: U.S. Market Size, by Research Phase, 2025-2035 (USD Billion)
Table 15: Canada Pharmaceutical CDMO Market Size, 2025-2035 (USD Billion)
Table 16: Canada Market Size, by Service Type, 2025-2035 (USD Billion)
Table 17: Canada Market Size, by Research Phase, 2025-2035 (USD Billion)
Table 18: Mexico Pharmaceutical CDMO Market Size, 2025-2035 (USD Billion)
Table 19: Mexico Market Size, by Service Type, 2025-2035 (USD Billion)
Table 20: Mexico Market Size, by Research Phase, 2025-2035 (USD Billion)
Table 21: North America Pharmaceutical CDMO Market Share, by Country, 2025 (%)
Table 22: North America Pharmaceutical CDMO Market Growth Forecast, 2025-2035 (USD Billion)

List of Figures

Figure 1: North America Pharmaceutical CDMO Market Forecast, 2025-2035 (USD Billion)
Figure 2: North America Pharmaceutical CDMO Market Share, by Service Type, 2025 (%)
Figure 3: North America Pharmaceutical CDMO Market Share, by Research Phase, 2025 (%)
Figure 4: North America Pharmaceutical CDMO Market Share, by Country, 2025 (%)
Figure 5: U.S. Pharmaceutical CDMO Market Forecast, 2025-2035 (USD Billion)
Figure 6: Canada Pharmaceutical CDMO Market Forecast, 2025-2035 (USD Billion)
Figure 7: Mexico Pharmaceutical CDMO Market Forecast, 2025-2035 (USD Billion)
Figure 8: North America API Manufacturing Market Forecast, 2025-2035 (USD Billion)
Figure 9: North America Finished Dosage Formulation (FDF) Development and Manufacturing Market Forecast, 2025-2035 (USD Billion)
Figure 10: North America Secondary Packaging Market Forecast, 2025-2035 (USD Billion)
Figure 11: North America Pre-clinical Phase CDMO Market Forecast, 2025-2035 (USD Billion)
Figure 12: North America Phase III CDMO Market Forecast, 2025-2035 (USD Billion)
Figure 13: North America Pharmaceutical CDMO Market Growth Opportunity Map, 2025-2035 (% CAGR)
Figure 14: North America Pharmaceutical CDMO Market Attractiveness Analysis, by Country, 2025 (%)

Research Methodology

Related Databooks

May 2026

April 2026